But the biotech’s newest update has failed to garner the same investor enthusiasm, with the company’s stock nearly halved following the data drop.
Chile has passed a bill outlawing the use of mobile phones and other smart devices during classes at elementary and middle ...
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response ...
The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant ...
ASH 2025 oral presentation on SENTI-202 in 20 Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) patients (18 response evaluable) shows high efficacy: 50% ORR and 42% CR/CRh (100% of CRs and 83% of ...
An Asheville man pleaded Dec. 8 to third degree child sexual exploitation after a sheriff's office detective uncovered child ...
We are delighted that isupartob sodium has been recognized as a first-in-class therapy through the award of its International Nonproprietary Name (INN), which includes a new and distinctive suffix.
Tens of millions of AT&T customers have just over a week to claim their share of a $177 million settlement stemming from two ...
bne IntelliNews on MSN
MARINS: The inexorable rise of the Chinese navy
By Patricia Marins in Rio de Janeiro The People's Liberation Army Navy (PLAN) of China continues to expand at a staggering ...
Kamuvudines are a new class of drugs that are derived from the anti-HIV nucleoside reverse transcriptase inhibitors. They are designed to inhibit the inflammasome, part of the innate immune system ...
Leronlimab treatment is associated with upregulation of PD-L1 in circulating tumor cells and cancer-associated macrophage-like cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback